Isabella Rimoldi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5367818/publications.pdf

Version: 2024-02-01

57	927	18	26
papers	citations	h-index	g-index
60	60	60	1164 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Hybrid Catalysts from Copper Biosorbing Bacterial Strains and Their Recycling for Catalytic Application in the Asymmetric Addition Reaction of B2(pin)2 on $\hat{l}\pm,\hat{l}^2$ -Unsaturated Chalcones. Catalysts, 2022, 12, 433.	3.5	5
2	Cytotoxicity of Alizarine versus Tetrabromocathecol Cyclometalated Pt(II) Theranostic Agents: A Combined Experimental and Computational Investigation. Inorganic Chemistry, 2022, 61, 7188-7200.	4.0	7
3	Exploring the copper binding ability of Mets7 hCtrâ€1 protein domain and His7 derivative: An insight in Michael addition catalysis. Journal of Peptide Science, 2021, 27, e3289.	1.4	9
4	Alternative Strategy to Obtain Artificial Imine Reductase by Exploiting Vancomycin/D-Ala-D-Ala Interactions with an Iridium Metal Complex. Inorganic Chemistry, 2021, 60, 2976-2982.	4.0	5
5	Promising Non-cytotoxic Monosubstituted Chalcones to Target Monoamine Oxidase-B. ACS Medicinal Chemistry Letters, 2021, 12, 1151-1158.	2.8	15
6	Reactions with Proteins of Three Novel Anticancer Platinum(II) Complexes Bearing N-Heterocyclic Ligands. International Journal of Molecular Sciences, 2021, 22, 10551.	4.1	8
7	New sp ³ diphosphine-based rhodium catalysts for the asymmetric conjugate addition of aryl boronic acids to 3-azaarylpropenones. New Journal of Chemistry, 2021, 45, 18769-18775.	2.8	5
8	In Vitro Activity of Monofunctional Pt-II Complex Based on 8-Aminoquinoline against Human Glioblastoma. Pharmaceutics, 2021, 13, 2101.	4.5	5
9	Novel 3,3-disubstituted oxindole derivatives. Synthesis and evaluation of the anti-proliferative activity. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126845.	2.2	17
10	Asymmetric Hydrogenation of 1-aryl substituted-3,4-Dihydroisoquinolines with Iridium Catalysts Bearing Different Phosphorus-Based Ligands. Catalysts, 2020, 10, 914.	3 . 5	4
11	Biological Properties of New Chiral 2-Methyl-5,6,7,8-tetrahydroquinolin-8-amine-based Compounds. Molecules, 2020, 25, 5561.	3.8	2
12	Antiproliferative effects of chalcones on T cell acute lymphoblastic leukemiaâ€derived cells: Role of PKCβ. Archiv Der Pharmazie, 2020, 353, 2000062.	4.1	7
13	Cytotoxic performances of new anionic cyclometalated Pt(II) complexes bearing chelated O^O ligands. Applied Organometallic Chemistry, 2020, 34, e5455.	3 . 5	12
14	Vancomycin-Iridium (III) Interaction: An Unexplored Route for Enantioselective Imine Reduction. Molecules, 2019, 24, 2771.	3.8	6
15	Monofunctional Pt ^{II} Complexes Based on 8â€Aminoquinoline: Synthesis and Pharmacological Characterization. European Journal of Inorganic Chemistry, 2019, 2019, 3389-3395.	2.0	18
16	Anticancer platinum(II) complexes bearing N-heterocycle rings. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1257-1263.	2.2	37
17	Synthesis and crystallographic structure of nickel(0) carbonyl complex with Bitianp, an atropoisomeric diphosphine. European Journal of Chemistry, 2019, 10, 171-174.	0.6	1
18	Exploiting coordination geometry to selectively predict the if -donor and $i\in$ -acceptor abilities of ligands: a back-and-forth journey between electronic properties and spectroscopy. Chemical Communications, 2018, 54, 2397-2400.	4.1	24

#	Article	IF	CITATIONS
19	Ruthenium(II) complexes bearing (NNN) ligand: catalytic evaluation of different solvent-mediated coordination modes. Canadian Journal of Chemistry, 2018, 96, 40-43.	1.1	6
20	8-Amino-5,6,7,8-tetrahydroquinoline in iridium(<scp>iii</scp>) biotinylated Cp* complex as artificial imine reductase. New Journal of Chemistry, 2018, 42, 18773-18776.	2.8	20
21	Novel platinum agents and mesenchymal stromal cells for thoracic malignancies: state of the art and future perspectives. Expert Opinion on Therapeutic Patents, 2018, 28, 813-821.	5.0	5
22	Uptake-release by MSCs of a cationic platinum(II) complex active in vitro on human malignant cancer cell lines. Biomedicine and Pharmacotherapy, 2018, 108, 111-118.	5.6	18
23	Asymmetric Hydrogenation <i>vs</i> Transfer Hydrogenation in the Reduction of Cyclic Imines. ChemistrySelect, 2018, 3, 8797-8800.	1.5	21
24	Cascade Reaction by Chemo―and Biocatalytic Approaches to Obtain Chiral Hydroxy Ketones and <i>anti</i> 1,3â€Diols. ChemistryOpen, 2018, 7, 393-400.	1.9	9
25	In vitro anticancer activity evaluation of new cationic platinum(II) complexes based on imidazole moiety. Bioorganic and Medicinal Chemistry, 2017, 25, 1907-1913.	3.0	29
26	Luminescent water-soluble cycloplatinated complexes: Structural, photophysical, electrochemical and chiroptical properties. Inorganica Chimica Acta, 2017, 461, 267-274.	2.4	17
27	On the relation between carbonyl stretching frequencies and the donor power of chelating diphosphines in nickel dicarbonyl complexes. Physical Chemistry Chemical Physics, 2017, 19, 9028-9038.	2.8	25
28	An inÂvivo active 1,2,5-oxadiazole Pt(II) complex: A promising anticancer agent endowed with STAT3 inhibitory properties. European Journal of Medicinal Chemistry, 2017, 131, 196-206.	5.5	37
29	Malignant Pleural Mesothelioma: State of the art and advanced cell therapy. European Journal of Medicinal Chemistry, 2017, 142, 266-270.	5.5	12
30	Mesenchymal Stromal Cells for Antineoplastic Drug Loading and Delivery. Medicines (Basel,) Tj ETQq0 0 0 rgBT	/Overlock	10 Tf 50 302 ⁻
31	Synthesis of new dithiolethione and methanethiosulfonate systems endowed with pharmaceutical interest. Arkivoc, 2017, 2017, 235-250.	0.5	2
32	Evaluation of Chemical Diversity of Biotinylated Chiral 1,3â€Diamines as a Catalytic Moiety in Artificial Imine Reductase. ChemCatChem, 2016, 8, 1665-1670.	3.7	25
33	Efficient methodology to produce a duloxetine precursor using whole cells of Rhodotorula rubra. Tetrahedron: Asymmetry, 2016, 27, 389-396.	1.8	12
34	Ctr-1 Mets7 motif inspiring new peptide ligands for Cu(<scp>i</scp>)-catalyzed asymmetric Henry reactions under green conditions. RSC Advances, 2016, 6, 71529-71533.	3.6	21
35	Vibrational circular dichroism and chiroptical properties of chiral Ir(<scp>iii</scp>) luminescent complexes. Dalton Transactions, 2016, 45, 992-999.	3.3	40
36	Luminescent chiral ionic Ir(III) complexes: Synthesis and photophysical properties. Journal of Luminescence, 2016, 170, 812-819.	3.1	16

#	Article	IF	Citations
37	Simple 1,3-diamines and their application as ligands in ruthenium(<scp>ii</scp>) catalysts for asymmetric transfer hydrogenation of aryl ketones. New Journal of Chemistry, 2015, 39, 3792-3800.	2.8	25
38	Electropolymerized Highly Photoconductive Thin Films of Cyclopalladated and Cycloplatinated Complexes. ACS Applied Materials & Samp; Interfaces, 2015, 7, 4019-4028.	8.0	23
39	Promising antiproliferative platinum(II) complexes based on imidazole moiety: synthesis, evaluation in HCT-116 cancer cell line and interaction with Ctr-1 Met-rich domain. Bioorganic and Medicinal Chemistry, 2015, 23, 2538-2547.	3.0	21
40	VCD spectroscopy as an excellent probe of chiral metal complexes containing a carbon monoxide vibrational chromophore. Chemical Communications, 2015, 51, 9385-9387.	4.1	10
41	Diastereoselectivity and catalytic activity in ruthenium complexes chiral at the metal centre. Journal of Organometallic Chemistry, 2014, 771, 2-8.	1.8	6
42	8-Amino-5,6,7,8-tetrahydroquinolines as ligands in iridium(III) catalysts for the reduction of aryl ketones by asymmetric transfer hydrogenation (ATH). Tetrahedron: Asymmetry, 2014, 25, 1031-1037.	1.8	28
43	Cytotoxic effect of (1-methyl-1 H -imidazol-2-yl)-methanamine and its derivatives in Pt II complexes on human carcinoma cell lines: A comparative study with cisplatin. Bioorganic and Medicinal Chemistry, 2013, 21, 2379-2386.	3.0	23
44	Enantioselective Transfer Hydrogenation of Aryl Ketones: Synthesis and 2D-NMR Characterization of New 8-amino-5,6,7,8-tetrahydroquinoline Ru(II)-complexes. Current Organic Chemistry, 2012, 16, 2982-2988.	1.6	19
45	"In situ―Activation of Racemic Ru ^{II} Complexes: Separation of <i>trans</i> and <i>cis</i> Species and Their Application in Asymmetric Reduction. European Journal of Inorganic Chemistry, 2012, 2012, 4365-4370.	2.0	20
46	Chemo- and biocatalytic strategies to obtain phenylisoserine, a lateral chain of Taxol by asymmetric reduction. Tetrahedron: Asymmetry, 2011, 22, 2110-2116.	1.8	18
47	3-(Hydroxy(phenyl)methyl)azetidin-2-ones obtained via catalytic asymmetric hydrogenation or by biotransformation. Tetrahedron: Asymmetry, 2011, 22, 597-602.	1.8	20
48	Histidine and deuterium-labelled histidine by asymmetric catalytic reduction and assignment of the absolute stereochemistry by neutron diffraction. Tetrahedron: Asymmetry, 2010, 21, 1162-1165.	1.8	5
49	Asymmetric reductions of ethyl 2-(benzamidomethyl)-3-oxobutanoate by yeasts. Tetrahedron: Asymmetry, 2009, 20, 411-414.	1.8	18
50	DIOPHEP, a chiral diastereoisomeric bisphosphine ligand: synthesis and applications in asymmetric hydrogenations. Tetrahedron: Asymmetry, 2008, 19, 1654-1659.	1.8	23
51	A tandem MS precursorâ€ion scan approach to identify variable covalent modification of albumin Cys34: a new tool for studying vascular carbonylation. Journal of Mass Spectrometry, 2008, 43, 1470-1481.	1.6	62
52	Histidine and deuterium labelled histidine by asymmetric catalytic reduction with gaseous H2 or D2; the role of strong non-coordinating acids. Tetrahedron: Asymmetry, 2008, 19, 273-278.	1.8	5
53	Chiral 1,4-bis-diphosphine ligands from optically active (Z)-olefines. Tetrahedron: Asymmetry, 2007, 18, 1278-1283.	1.8	12
54	Fast-dissolving mucoadhesive microparticulate delivery system containing piroxicam. European Journal of Pharmaceutical Sciences, 2005, 24, 355-361.	4.0	35

#	Article	IF	CITATIONS
55	Stereoselective synthesis of 1-methylcarbapenem precursors: studies on the diastereoselective hydroformylation of 4-vinyl β-lactam with aminophosphonite–phosphinite and aminophosphine–phosphite rhodium(I) complexes. Tetrahedron: Asymmetry, 2004, 15, 3841-3845.	1.8	18
56	Aminophosphonite-phosphite and aminophosphonite-phosphinite ligands with mixed chirality: preparation and catalytic applications in asymmetric hydrogenation and hydroformylation. Journal of Molecular Catalysis A, 2003, 204-205, 211-220.	4.8	16
57	Enantioselective Mukaiyama aldol and Sakurai allylation reactions catalysed by silver(I) complexes with chiral atropisomeric chelating ligands. Journal of Molecular Catalysis A, 2003, 204-205, 221-226.	4.8	10